Bent Ejlertsen

Summary

Country: Denmark

Publications

  1. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
  2. pmc Novel de novo BRCA2 mutation in a patient with a family history of breast cancer
    Thomas V O Hansen
    Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark
    BMC Med Genet 9:58. 2008
  3. ncbi [Hereditary breast cancer: treatment and prevention]
    Bent Ejlertsen
    Rigshospitalet, Finsencentret, Onkologisk Klinik, København Ø
    Ugeskr Laeger 169:2972-5. 2007
  4. ncbi [Medical treatment of early breast cancer: chemotherapy]
    Bent Ejlertsen
    Rigshospitalet, Finsencentret, Onkologisk Klinik, København Ø
    Ugeskr Laeger 169:3070-2. 2007
  5. ncbi [Should chemotherapy or endocrine therapy be used as first choice in patients with advanced breast cancer? A status article based on the Cochrane analysis "Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer"]
    Bent Ejlertsen
    H S Rigshospitalet, Finsencentret, Onkologisk Klinik, København
    Ugeskr Laeger 166:2434-6. 2004
  6. doi Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer
    Bent Kristensen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:740-6. 2008
  7. doi The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D
    Kirsten Vang Nielsen
    Dako A S, Glostrup, Denmark
    Acta Oncol 47:725-34. 2008
  8. doi DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients
    Bent Ejlertsen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:709-17. 2008
  9. doi Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89
    Bent Ejlertsen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:662-71. 2008
  10. ncbi Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study
    Lisbeth Bertelsen
    Institute of Cancer Epidemiology, Danish Cancer Society, Strandboulevarden 49, DK 2100 Copenhagen Ø, Denmark
    J Natl Cancer Inst 100:32-40. 2008

Collaborators

Detail Information

Publications28

  1. pmc Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan
    Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
    Breast Cancer Res 13:R110. 2011
    ..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...
  2. pmc Novel de novo BRCA2 mutation in a patient with a family history of breast cancer
    Thomas V O Hansen
    Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark
    BMC Med Genet 9:58. 2008
    ..We describe the parental origin and functional characterization of a novel de novo BRCA2 splice site mutation found in a patient exhibiting a ductal carcinoma at the age of 40...
  3. ncbi [Hereditary breast cancer: treatment and prevention]
    Bent Ejlertsen
    Rigshospitalet, Finsencentret, Onkologisk Klinik, København Ø
    Ugeskr Laeger 169:2972-5. 2007
    ..The possible impact of BRCA1/2 mutations on the efficacy of medical therapies has recently attained much interest, alongside the development of targeted therapies against BRCA1/2 associated cancers...
  4. ncbi [Medical treatment of early breast cancer: chemotherapy]
    Bent Ejlertsen
    Rigshospitalet, Finsencentret, Onkologisk Klinik, København Ø
    Ugeskr Laeger 169:3070-2. 2007
    ..A regimen containing anthracyclines and taxanes, the most active drugs in primary breast cancer, is preferable if chemotherapy is to be used, e.g. epirubicin and cyclophosphamide followed by docetaxel...
  5. ncbi [Should chemotherapy or endocrine therapy be used as first choice in patients with advanced breast cancer? A status article based on the Cochrane analysis "Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer"]
    Bent Ejlertsen
    H S Rigshospitalet, Finsencentret, Onkologisk Klinik, København
    Ugeskr Laeger 166:2434-6. 2004
  6. doi Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer
    Bent Kristensen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:740-6. 2008
    ..The patients received adjuvant chemotherapy, loco-regional radiation therapy, but no endocrine treatment...
  7. doi The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D
    Kirsten Vang Nielsen
    Dako A S, Glostrup, Denmark
    Acta Oncol 47:725-34. 2008
    ..We present an updated and extended statistical analysis, requested for IVD-labeling of TOP2A testing...
  8. doi DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients
    Bent Ejlertsen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:709-17. 2008
    ..A cohort of premenopausal patients with primary hormone receptor positive breast cancer was prospectively identified to be eligible for the DBCG 89B trial. We perform a long-term follow-up and evaluate the external validity of the trial...
  9. doi Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89
    Bent Ejlertsen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:662-71. 2008
    ..The classical CMF has later been modified as concerns dose and schedule, without formal comparisons in randomised trials between the classical CMF and the modifications...
  10. ncbi Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study
    Lisbeth Bertelsen
    Institute of Cancer Epidemiology, Danish Cancer Society, Strandboulevarden 49, DK 2100 Copenhagen Ø, Denmark
    J Natl Cancer Inst 100:32-40. 2008
    ..However, less is known about how long the risk is reduced and the impact of factors such as age and menopausal status...
  11. ncbi Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer
    Bent Ejlertsen
    Department of Oncology, Bldg 5012 Rigshospitalet, Copenhagen University Hospital, 9 Blegdamsvej, DK 2100 Copenhagen, Denmark
    Eur J Cancer 43:877-84. 2007
    ..The risk of secondary leukaemia and congestive heart failure was similar in the two groups. Overall CEF was superior over CMF in terms of DFS and OS in patients with operable breast cancer without subsequent increase in late toxicities...
  12. ncbi [Inherited breast and ovarian cancers]
    Anne Marie A Gerdes
    Odense Universitetshospital, Afdeling for Biokemi, Farmakologi og Genetik, DK 5000 Odense C
    Ugeskr Laeger 168:2367-9. 2006
    ..National guidelines for clinical intervention in the cases of high-risk individuals have been established...
  13. ncbi Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer
    Bent Ejlertsen
    Department of Oncology, Bldg 5012 Rigshospitalet, Copenhagen University Hospital, DK 2100 Copenhagen, Denmark
    J Clin Oncol 24:4956-62. 2006
    ..To compare the efficacy of ovarian ablation versus chemotherapy in early breast cancer patients with hormone receptor-positive disease...
  14. ncbi retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danis
    Ann S Knoop
    Oncological Department, Odense University Hospital DK 5000, Odense C, Denmark
    J Clin Oncol 23:7483-90. 2005
    ..The aim of the study was to evaluate the predictive value of HER2 and topoisomerase IIalpha gene (TOP2A) for the efficacy of epirubicin in the adjuvant setting of breast cancer patients...
  15. ncbi [Preoperative chemotherapy in operable breast cancer. A survey of a Cochrane review]
    Mogens Bernsdorf Petersen
    Onkologisk Klinik 5073, Rigshospitalet, DK 2100 København Ø
    Ugeskr Laeger 170:3048-50. 2008
  16. ncbi [The effect of bisphosphonates on pain relief in patients with bone metastases: A status article based on the Cochrane analysis: "Bisphosphonates for the relief of pain secondary to bone metastasis"]
    Bent Ejlertsen
    Onkologisk Klinik 5012, H S Rigshospitalet, Blegdamsvej 9, DK 2100 København Ø
    Ugeskr Laeger 165:2089-91. 2003
  17. ncbi Aromatase inhibitors in the treatment of early and advanced breast cancer
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    Acta Oncol 44:23-31. 2005
    ..Third generation aromatase inhibitors may be considered as the first line therapy of hormone-receptor-positive advanced breast cancer in postmenopausal women, and they may also be used for preoperative therapy of breast cancer...
  18. doi Vinorelbine as first-line or second-line therapy for advanced breast cancer: a Phase I-II trial by the Danish Breast Cancer Co-operative Group
    Sven T Langkjer
    Department of Oncology, Vejle Sygehus, Vejle, Denmark
    Acta Oncol 47:735-9. 2008
    ..This study was conducted to establish the maximum tolerated dose (MTD) of intravenous vinorelbine and on the determined dose to assess efficacy and safety in patients with metastatic breast cancer previously treated with epirubicin...
  19. doi Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)
    Jørn Andersen
    Department of Oncology, Arhus University Hospital, Arhus Sygehus, Denmark
    Acta Oncol 47:718-24. 2008
    ..A multivariate analysis in the per-protocol treated patients did not show significant differences in hazard ratios for DFS or OS among the three arms. Side-effects were rare but more common in the TAM2 and TAM/MA arms...
  20. pmc Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays
    Katrine L Henriksen
    Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen Ø, Denmark
    J Clin Pathol 60:397-404. 2007
    ..To assess whether immunohistochemically stained tissue microarrays (TMA) of 2 mm cores from paraffin embedded tumour tissue may replace whole sections in semi-quantitative evaluation of selected potential markers for endocrine treatment...
  21. ncbi [Future endocrine therapy of breast cancer]
    Bent Ejlertsen
    Ugeskr Laeger 169:296. 2007
  22. doi Pregnancy after treatment of breast cancer--a population-based study on behalf of Danish Breast Cancer Cooperative Group
    Niels Kroman
    Department of Breast and Endocrine Surgery, Rigshospitalet, Copenhagen, Denmark
    Acta Oncol 47:545-9. 2008
    ..In 1997 we published a population-based Danish study indicating no negative prognostic effect of pregnancy after breast cancer treatment. The present study is a ten-year update...
  23. doi The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise
    Susanne Møller
    Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark
    Acta Oncol 47:506-24. 2008
    ..Discussion. The joint conception of the multidisciplinary breast cancer group and a clinical database has provided improvements in the management of breast cancer patients and has enabled recruitment of patients onto randomised trials...
  24. ncbi [Press, ethics and genetic screening]
    Anne Marie Gerdes
    Ugeskr Laeger 168:3448; author reply 3448. 2006
  25. ncbi Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes
    Karen E Olsen
    Department of Pathology, Odense University Hospital, Denmark
    Acta Oncol 43:35-42. 2004
    ..Traditionally, in the FISH technique the result has been based on counting 60 cells. However, we found that a much less time-consuming method of counting 60 signals gave equally good results...
  26. ncbi Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403)
    Bent Ejlertsen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    J Clin Oncol 22:2313-20. 2004
    ..To determine whether the addition of intravenous (IV) vinorelbine to epirubicin increased the progression-free survival in first-line treatment of metastatic breast cancer...
  27. ncbi Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer
    Jan Trøst Jørgensen
    Clinical Research, Dako Denmark A S, Produktionsvej 42, DK 2600 Glostrup, Denmark
    Oncologist 12:397-405. 2007
    ..Pharmacodiagnostic tests will play an important role in the further development of targeted therapies and may be seen as a prerequisite for the introduction of individualized medicine in oncology...
  28. ncbi [Breast cancer]
    Mogens Blichert-Toft
    H S Rigshospitalet, endokrin and mammakirurgisk klinik CE, Finsencentret, Onkologisk afdeling
    Ugeskr Laeger 164:3023-6. 2002